| Market cap | $278.68M |
|---|---|
| Enterprise value | $24.03M |
| Revenue | $0.00 |
|---|---|
| EBITDA | -$40.15 |
| Income | -$46.28 |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E | 6.18 |
|---|---|
| Forward P/E | N/A |
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| PEG | N/A |
| Price/Sales | N/A |
| P/FCF | N/A |
| Price/Book | 116.09 |
| Book/Share | 0.00 |
| Cash/Share | 0.00 |
| FCF yield | -13.36% |
| Volume | 8.194M / 50.829k |
|---|---|
| Relative vol. | 161.21 × |
| EPS | N/A |
|---|---|
| EPS Q/Q | -28.00% |
| Est. EPS Q/Q | 6.25% |
| Profit margin | 0.00% |
|---|---|
| Oper. margin | N/A |
| Gross margin | N/A |
| EBIT margin | N/A |
| EBITDA margin | N/A |
| Ret. on assets | -159.45% |
|---|---|
| Ret. on equity | -584.98% |
| ROIC | -98.65% |
| ROCE | 684.23% |
| Debt/Equity | 12.81 |
|---|---|
| Net debt/EBITDA | 1.56 |
| Current ratio | 0.59 |
| Quick ratio | 0.59 |
| Volatility | 40.77% |
|---|---|
| Beta | 0.54 |
| RSI | 32.36 |
|---|
| Insider ownership | 1.29% |
|---|---|
| Inst. ownership | 21.66% |
| Shares outst. | 255.668M |
|---|---|
| Shares float | 12.081M 4.73% |
| Short % of float | 0.97% |
| Short ratio | 1.07 |
| Dividend | N/A |
|---|---|
| Dividend yield | N/A |
| Payout ratio | N/A |
| Payment date | N/A |
| Ex-dividend date | N/A |
| Earnings date | N/A |
Wednesday, 22 June 2022
|
|
| Raleigh pharma sees stock tumble after stopping trial. Now what? | |
Thursday, 4 February 2021
|
|
| 9 Meters Biopharma is Overbought: Is A Drop Coming? | |
Wednesday, 2 December 2020
|
|
| Is 9 Meters Biopharma A Good Stock To Buy Now? | |
Monday, 13 July 2020
|
|
| SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating 9 Meters Biopharma, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors | |
| Insider |
Trans.
Transaction
|
Total value |
|---|---|---|
| Bethany Sensenig Chief Financial Officer | Sale 21 Apr 2023 | $11,011 |
| John Temperato Chief Executive Officer | Buy 6 Jul 2022 | $28,750 |
| Mark A Sirgo Director | Buy 1 Jul 2022 | $43,750 |
| Michael T. Constantino Director | Buy 23 May 2022 | $7,680 |
| John Temperato Chief Executive Officer | Buy 18 May 2022 | $22,500 |
| Mark A Sirgo Director | Buy 18 May 2022 | $50,000 |
| Mark A Sirgo Director | Buy 3 Mar 2022 | $50,140 |
| John Temperato Chief Executive Officer | Buy 3 Mar 2022 | $56,000 |
| Mark A Sirgo Director | Buy 2 Dec 2021 | $44,500 |
| Mark A Sirgo Director | Buy 18 Nov 2021 | $21,200 |
| John Temperato Chief Executive Officer | Buy 18 Nov 2021 | $52,500 |
Powered by
Robintrack.
| Insider | Age | Since | Compensation |
|---|---|---|---|
| John Temperato (56) Pres, CEO, and Director | 56 | $652,437 | |
| Dr. Patrick H. Griffin (66) Chief Medical Officer | 66 | $500,550 | |
| Edward J. Sitar CPA, CPA (58) Chief Financial Officer | 58 | $397,400 | |
| Sarah Liu M.B.A. | |||
| Albert J. Medwar M.B.A., MBA | |||
| Bethany Sensenig C.M.A., M.B.A. | |||
| Dr. Nir Barak M.D. | |||
| Dr. Elena Verdu M.D., Ph.D. | |||
| Dr. Ciaran P. Kelly M.D. | |||
| Joseph A. Murray | |||
| Dr. Peter H. R. Green M.D. | |||
| Dr. Nir Barak | |||
| Jerry Gardner | |||
| Sireesh Appajosyula Pharm.D. (45) Sr. VP of Corp. Devel. and Operations | 45 |
9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders. The company is developing Larazotide, an 8-amino acid peptide, which is in Phase 3 clinical trial for the treatment of celiac disease, as well as in Phase IIa clinical trial for treatment of multi-system inflammatory syndrome; and Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 2 clinical trial to treat short bowel syndrome. It also develops NM-102, a small molecule peptide; NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease; NM-136, a humanized monoclonal antibody for targeted obesity disorders; and NM-004, a double-cleaved mesalamine with an immunomodulator for rare and/or orphan indications. The company is based in Raleigh, North Carolina.
- Health Care > Biotechnology
- 9 Meters Biopharma, Inc., 8480 Honeycutt Road, Raleigh 27615, United States
- 919 275 1933
- Investor relations
Quarterly EPS estimates
Profit margin
Debt to assets
Cash flow
Balance sheet
XSLX
| (in millions USD) | 31 Mar 2023 | 31 Dec 2022 | |||
|---|---|---|---|---|---|
| Current assets | |||||
| Cash | $7.623578 | $29.658932 | |||
| Short term investments | |||||
| Net receivables | |||||
| Inventory | |||||
| Total current assets | $9.197303 | $33.017849 | |||
| Long term investments | |||||
| Property, plant & equipment | $0.106754 | $0.122715 | |||
| Goodwill & intangible assets | |||||
| Total noncurrent assets | $0.115734 | $0.129995 | |||
| Total investments | |||||
| Total assets | $9.313037 | $33.147844 | |||
| Current liabilities | |||||
| Accounts payable | $4.231034 | $5.053073 | |||
| Deferred revenue | |||||
| Short long term debt | $5.071143 | $19.616313 | |||
| Total current liabilities | $15.577469 | $30.695905 | |||
| Long term debt | $0.034773 | $0.051396 | |||
| Total noncurrent liabilities | $0.034773 | $0.051396 | |||
| Total debt | $5.105916 | $19.667709 | |||
| Total liabilities | $15.612242 | $30.747301 | |||
| Stockholders' equity | |||||
| Retained earnings | -$226.475539 | -$212.607082 | |||
| Other stockholder equity | |||||
| Total stockholder equity | -$6.299205 | $2.400543 | |||
| (in millions USD) | 2022 | 2021 | ||
|---|---|---|---|---|
| Current assets | ||||
| Cash | $29.658932 | $46.993285 | ||
| Short term investments | ||||
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $33.017849 | $49.985233 | ||
| Long term investments | ||||
| Property, plant & equipment | $0.122715 | $0.182712 | ||
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $0.129995 | $0.188292 | ||
| Total investments | ||||
| Total assets | $33.147844 | $50.173525 | ||
| Current liabilities | ||||
| Accounts payable | $5.053073 | $2.434452 | ||
| Deferred revenue | ||||
| Short long term debt | $19.616313 | |||
| Total current liabilities | $30.695905 | $8.45707 | ||
| Long term debt | $0.051396 | $0.113142 | ||
| Total noncurrent liabilities | $0.051396 | $0.113142 | ||
| Total debt | $19.667709 | $0.113142 | ||
| Total liabilities | $30.747301 | $8.570212 | ||
| Stockholders' equity | ||||
| Retained earnings | -$212.607082 | -$168.840667 | ||
| Other stockholder equity | ||||
| Total stockholder equity | $2.400543 | $41.603313 | ||
Income statement
| (in millions USD) | 31 Mar 2023 | 31 Dec 2022 | |||
|---|---|---|---|---|---|
| Revenue | |||||
| Total revenue | |||||
| Cost of revenue | |||||
| Gross profit | |||||
| Operating activities | |||||
| Research & development | $9.799291 | $8.794695 | |||
| Selling, general & administrative | $2.9882 | $1.946701 | |||
| Total operating expenses | $12.787491 | $10.741396 | |||
| Operating income | -$12.787491 | -$10.741396 | |||
| Income from continuing operations | |||||
| EBIT | -$13.115637 | -$10.110259 | |||
| Income tax expense | |||||
| Interest expense | $0.75282 | $1.819644 | |||
| Net income | |||||
| Net income | -$13.868457 | -$11.929903 | |||
| Income (for common shares) | -$13.868457 | -$11.929903 | |||
| (in millions USD) | 2022 | 2021 | ||
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross profit | ||||
| Operating activities | ||||
| Research & development | $31.008151 | $21.995291 | ||
| Selling, general & administrative | $11.0089 | $9.662875 | ||
| Total operating expenses | $42.017051 | $36.761919 | ||
| Operating income | -$42.017051 | -$36.761919 | ||
| Income from continuing operations | ||||
| EBIT | -$41.099126 | -$36.732212 | ||
| Income tax expense | ||||
| Interest expense | $2.667289 | $0.047188 | ||
| Net income | ||||
| Net income | -$43.766415 | -$36.7794 | ||
| Income (for common shares) | -$43.766415 | -$36.7794 | ||
Cash flows
| (in millions USD) | 31 Mar 2023 | 31 Dec 2022 | |||
|---|---|---|---|---|---|
| Net income | -$13.868457 | -$11.929903 | |||
| Operating activities | |||||
| Depreciation | $0.001329 | $0.00254 | |||
| Business acquisitions & disposals | |||||
| Stock-based compensation | $0.737 | $0.744 | |||
| Total cash flows from operations | -$9.749676 | -$9.73861 | |||
| Investing activities | |||||
| Capital expenditures | |||||
| Investments | |||||
| Total cash flows from investing | |||||
| Financing activities | |||||
| Dividends paid | |||||
| Sale and purchase of stock | $5 | ||||
| Net borrowings | -$16.748001 | ||||
| Total cash flows from financing | -$12.285678 | ||||
| Effect of exchange rate | |||||
| Change in cash and equivalents | -$22.035354 | -$9.73861 | |||
| (in millions USD) | 2022 | 2021 | ||
|---|---|---|---|---|
| Net income | -$43.766415 | -$36.7794 | ||
| Operating activities | ||||
| Depreciation | $0.008523 | $0.007573 | ||
| Business acquisitions & disposals | -$2.493165 | |||
| Stock-based compensation | $3.938 | $2.413 | ||
| Total cash flows from operations | -$37.243217 | -$29.478275 | ||
| Investing activities | ||||
| Capital expenditures | -$0.002842 | -$0.012476 | ||
| Investments | $0.075 | |||
| Total cash flows from investing | -$0.002842 | -$2.430641 | ||
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $44.010135 | |||
| Net borrowings | $19.911706 | -$0.058199 | ||
| Total cash flows from financing | $19.911706 | $41.050813 | ||
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$17.334353 | $9.141897 | ||
Recent institutional transactions
| Quarter | Shareholder | Change |
Shares owned
Shares
|
Value (in thousands USD) |
|---|---|---|---|---|
| 2023 Q3 | Strategic Investment Solutions, il |
+6,200.00%
|
17,325 | $2,284 |
| 2023 Q2 | Sabby Management |
Sold out
|
1,038,440 | $697,832 |
| 2023 Q2 | Vanguard Group Inc |
Sold out
|
619,829 | $416,526 |
| 2023 Q2 | Laurion Capital Management L.P. |
Opened
|
218,710 | $146,973 |
| 2023 Q2 | Two Sigma Securities |
Sold out
|
13,844 | $9,303 |
| 2023 Q2 | Group One Trading, L.P. |
Sold out
|
10,363 | $6,964 |
| 2023 Q2 | Fmr |
Sold out
|
53 | $36 |
| 2023 Q1 | Northwestern Mutual Wealth Management Co |
Sold out
|
2 | $3 |
| 2022 Q4 | Renaissance Technologies |
Sold out
|
73,168 | $92 |
| 2022 Q3 | Laurion Capital Management L.P. |
Sold out
|
4,558,200 | $980 |
Institutional shareholders
| Shareholder | Stake |
Shares owned
Shares
|
Value (in thousands USD) |
|---|---|---|---|
| Laurion Capital Management L.P. | 1.87% | 4,776,910 | |
| Sabby Management | 0.41% | 1,038,440 | |
| Millennium Management | 0.38% | 958,880 | |
| Vanguard Group Inc | 0.24% | 619,829 | |
| Renaissance Technologies | 0.03% | 73,168 | |
| Regentatlantic Capital | 0.02% | 41,322 | |
| Amalgamated | 0.01% | 36,861 | |
| Ashfield Capital Partners | 0.01% | 33,353 | |
| Frontier Wealth Management | 0.01% | 30,000 | |
| Citadel Advisors | 0.01% | 27,808 |
Sign up